Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug testing in children.

J Greene

    FDA Consumer
    |May 12, 1978
    PubMed
    Summary

    Pediatric drug testing is limited, forcing doctors to extrapolate adult data for children's medication. New guidelines aim to encourage manufacturers to conduct essential pediatric drug studies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The economics of febrile neutropenia: implications for the use of colony-stimulating factors.

    European journal of cancer (Oxford, England : 1990)·1999
    Same author

    Direct contracts. Running for coverage.

    Hospitals & health networks·1999
    Same author

    Quackery. Muddled miracles.

    Hospitals & health networks·1999
    Same author

    A stormy season for rurals.

    Hospitals & health networks·1998
    Same author

    Melatonin for the masses. Antiaging entrepreneurs peddle therapies that promise to cheat the clock.

    Hospitals & health networks·1998
    Same author

    Nurse shortage. Where have all the RNs gone?

    Hospitals & health networks·1998

    Area of Science:

    • Pediatric Pharmacology
    • Drug Development
    • Regulatory Science

    Background:

    • Limited clinical trials in pediatric populations lead to a lack of approved medications for children.
    • Physicians frequently rely on adult drug data, necessitating dose extrapolation for pediatric use.
    • Manufacturer reluctance to conduct pediatric drug studies presents a significant barrier to evidence-based treatment.

    Purpose of the Study:

    • To address the deficit of pediatric-specific drug information.
    • To facilitate the development of new testing guidelines for pediatric drug studies.
    • To encourage pharmaceutical manufacturers to undertake drug research in pediatric populations.

    Main Methods:

    • Development of new drug testing guidelines by the American Academy of Pediatrics.
    • Focus on creating a framework to overcome manufacturer reluctance for pediatric studies.

    Main Results:

    • New guidelines have been developed by the American Academy of Pediatrics.
    • These guidelines are intended to improve the process of pediatric drug testing.

    Conclusions:

    • The new guidelines are expected to increase the number of drugs tested in children.
    • This initiative aims to improve the safety and efficacy of medications used in pediatric care.
    • Enhanced pediatric drug testing will support informed clinical decision-making for children's health.

    Related Experiment Videos